Patient Advocacy Organizations (PAOs) Thrilled With Biogen’s Aduhelm Approval As Northeastern and Yale Experts Call for Revised Scope of PAOs
Patient advocacy groups (PAOs) look to drugs receiving accelerated approval from the Food and Drug Administration, such as the contentious [...]
Biogen’s Aduhelm Price Tag Too High Says ICER
The Institute for Clinical and Economic Review (ICER) published a revised report on Biogen’s Aduhelm. The drug is designed for [...]
ICER Finds Insufficient Clinical Benefit for Controversial Alzheimer’s Drug in Revised Report and Calls for Price Reduction Ahead of CTAF meeting
The Institute for Clinical and Economic Review (ICER) has issued a revised evidence report on Biogen’s Aduhelm, or aducanumab. ICER [...]
Biogen Partners with Cigna and CVS Health to Promote Access to Contentious Alzheimer’s Drug
Biogen has announced that it will partner with Cigna and CVS Health to improve patient access to aducanumab, which received [...]
Advertisement
